These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 35715969)
21. Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia. Nakatani T; Imamura T; Ishida H; Wakaizumi K; Yamamoto T; Otabe O; Ishigami T; Adachi S; Morimoto A Pediatr Blood Cancer; 2008 Dec; 51(6):802-5. PubMed ID: 18802948 [TBL] [Abstract][Full Text] [Related]
22. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond. Michiels JJ; Berneman Z; Schroyens W; De Raeve H Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092 [TBL] [Abstract][Full Text] [Related]
23. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations. Turakhia SK; Murugesan G; Cotta CV; Theil KS J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830 [TBL] [Abstract][Full Text] [Related]
24. De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia. Hsiao HH; Ito Y; Sashida G; Ohyashiki JH; Ohyashiki K Leuk Res; 2005 Nov; 29(11):1247-52. PubMed ID: 16164981 [TBL] [Abstract][Full Text] [Related]
25. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications. Malak S; Labopin M; Saint-Martin C; Bellanne-Chantelot C; Najman A; Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):170-6. PubMed ID: 22818858 [TBL] [Abstract][Full Text] [Related]
26. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis. Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192 [TBL] [Abstract][Full Text] [Related]
27. Progression of coronary calcium burden and carotid stiffness in patients with essential thrombocythemia associated with JAK2 V617F mutation. Anžič Drofenik A; Vrtovec M; Božič Mijovski M; Sever M; Preložnik Zupan I; Kejžar N; Blinc A Atherosclerosis; 2020 Mar; 296():25-31. PubMed ID: 32005002 [TBL] [Abstract][Full Text] [Related]
28. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. De Stefano V; Za T; Rossi E; Fiorini A; Ciminello A; Luzzi C; Chiusolo P; Sica S; Leone G Haematologica; 2009 May; 94(5):733-7. PubMed ID: 19336736 [TBL] [Abstract][Full Text] [Related]
29. Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review. Marchetti M; Carobbio A; Capitoni E; Barbui T Am J Hematol; 2018 May; 93(5):698-703. PubMed ID: 29377227 [TBL] [Abstract][Full Text] [Related]
30. JAK2 V617F-positive essential thrombocythemia in a patient with Klinefelter syndrome: a case report. Yhim HY; Kim HS; Sohn JY; Song MJ; Lee NR; Song EK; Choi SI; Yim CY; Kwak JY Cancer Genet Cytogenet; 2010 Apr; 198(2):162-5. PubMed ID: 20362232 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera. Karkucak M; Yakut T; Ozkocaman V; Ozkalemkas F; Ali R; Bayram M; Gorukmez O; Ocakoglu G Mol Biol Rep; 2012 Sep; 39(9):8663-7. PubMed ID: 22722988 [TBL] [Abstract][Full Text] [Related]
32. Essential thrombocythemia during treatment of acute myeloid leukemia with JAK2 V617F mutation: A case report of a CARE-compliant article. Ding W; Li D; Zhuang C; Wei P; Mou W; Zhang L; Liang H; Liu Y Medicine (Baltimore); 2018 Jul; 97(27):e11331. PubMed ID: 29979407 [TBL] [Abstract][Full Text] [Related]
33. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype. Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178 [TBL] [Abstract][Full Text] [Related]
34. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera. Rottenstreich A; Kleinstern G; Krichevsky S; Varon D; Lavie D; Kalish Y Eur J Intern Med; 2017 Jun; 41():49-54. PubMed ID: 27919526 [TBL] [Abstract][Full Text] [Related]
35. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era. Zhan H; Spivak JL Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323 [TBL] [Abstract][Full Text] [Related]
37. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF). Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893 [TBL] [Abstract][Full Text] [Related]
38. Activation of the tissue factor-dependent extrinsic pathway and its relation to JAK2 V617F mutation status in patients with essential thrombocythemia. Gadomska G; Stankowska K; Boinska J; Bartoszewska-Kubiak A; Haus O; Rość D Blood Coagul Fibrinolysis; 2016 Oct; 27(7):817-821. PubMed ID: 26945263 [TBL] [Abstract][Full Text] [Related]
39. Two faces of ET: CALR and JAK2. Chao MP; Gotlib J Blood; 2014 Mar; 123(10):1438-40. PubMed ID: 24627549 [TBL] [Abstract][Full Text] [Related]
40. Essential thrombocythemia: scientific advances and current practice. Tefferi A Curr Opin Hematol; 2006 Mar; 13(2):93-8. PubMed ID: 16456375 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]